50 related articles for article (PubMed ID: 27490759)
1. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
2. Parathyroid carcinoma arising from four-gland hyperplasia.
Kauffmann RM; Juhlin CC; Fohn LE; Broome JT; Phay JE
Endocr Pract; 2011; 17(2):e37-42. PubMed ID: 21247853
[TBL] [Abstract][Full Text] [Related]
3. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
Cetani F; Banti C; Pardi E; Borsari S; Viacava P; Miccoli P; Torregrossa L; Basolo F; Pelizzo MR; Rugge M; Pennelli G; Gasparri G; Papotti M; Volante M; Vignali E; Saponaro F; Marcocci C
Endocr Connect; 2013; 2(4):186-95. PubMed ID: 24145611
[TBL] [Abstract][Full Text] [Related]
4. Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment.
Juhlin CC
Endocr Pathol; 2024 Mar; 35(1):84-87. PubMed ID: 38363524
[No Abstract] [Full Text] [Related]
5. Immunohistochemistry in Diagnostic Parathyroid Pathology.
Erickson LA; Mete O
Endocr Pathol; 2018 Jun; 29(2):113-129. PubMed ID: 29626276
[TBL] [Abstract][Full Text] [Related]
6. Tertiary hyperparathyroidism masking an atypical parathyroid tumor.
Laskou S; Kountouri I; Paschou E; Topalidis C; Axi P; Petrakis G; Kosmidis C; Sapalidis K
Clin Case Rep; 2024 Apr; 12(4):e8753. PubMed ID: 38617065
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Profile of Primary Hyperparathyroidism with Special Reference to Ki-67 Labelling Index.
Thanveer AS; Kamalanathan S; Badhe BA; Palui R; Rashmi KG; Nadeem NF
Indian J Endocrinol Metab; 2023; 27(1):73-79. PubMed ID: 37215275
[TBL] [Abstract][Full Text] [Related]
8. Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.
Popow M; Kaszczewska M; Góralska M; Kaszczewski P; Skwarek-Szewczyk A; Chudziński W; Jażdżewski K; Kolanowska M; Bogdańska M; Starzyńska-Kubicka A; Gałązka Z
Am J Case Rep; 2022 Oct; 23():e936135. PubMed ID: 36271606
[TBL] [Abstract][Full Text] [Related]
9. Association of Parathyroid and Differentiated Thyroid Carcinomas: A Narrative Up-To-Date Review of the Literature.
Simescu R; Pop M; Piciu A; Muntean V; Piciu D
Medicina (Kaunas); 2022 Aug; 58(9):. PubMed ID: 36143862
[No Abstract] [Full Text] [Related]
10. GIANT MEDIASTINAL PARATHYROID ADENOMAS AND MULTIPLE ENDOCRINE NEOPLASIA TYPE 1: A DIAGNOSTIC CONUNDRUM.
Gautam A; Rastogi A; Bhadada SK
Acta Endocrinol (Buchar); 2022; 18(1):118-123. PubMed ID: 35975263
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.
Uljanovs R; Sinkarevs S; Strumfs B; Vidusa L; Merkurjeva K; Strumfa I
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805976
[TBL] [Abstract][Full Text] [Related]
12. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
13. Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas.
Yavropoulou MP; Pazaitou-Panayiotou K; Yovos JG; Poulios C; Anastasilakis AD; Vlachodimitropoulos D; Vambakidis K; Tsave O; Chrisafi S; Daskalaki E; Makras P
JBMR Plus; 2021 Feb; 5(2):e10431. PubMed ID: 33615103
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing Parathyromatosis, Atypical Parathyroid Adenomas, and Parathyroid Carcinomas Utilizing Histologic and Clinical Features.
Schulte JJ; Pease G; Taxy JB; Hall C; Cipriani NA
Head Neck Pathol; 2021 Sep; 15(3):727-736. PubMed ID: 33394375
[TBL] [Abstract][Full Text] [Related]
15. Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.
Juhlin CC; Erickson LA
Endocr Pathol; 2021 Mar; 32(1):17-34. PubMed ID: 33269427
[TBL] [Abstract][Full Text] [Related]
16. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.
Silva-Figueroa AM; Bassett R; Christakis I; Moreno P; Clarke CN; Busaidy NL; Grubbs EG; Lee JE; Perrier ND; Williams MD
Endocr Pathol; 2019 Dec; 30(4):285-296. PubMed ID: 31734935
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid Neoplasms: Immunohistochemical Characterization and Long Noncoding RNA (lncRNA) Expression.
Yu Q; Hardin H; Chu YH; Rehrauer W; Lloyd RV
Endocr Pathol; 2019 Jun; 30(2):96-105. PubMed ID: 31119524
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT.
Pyo JS; Cho WJ
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30926677
[TBL] [Abstract][Full Text] [Related]
19. A Role for Circular Non-Coding RNAs in the Pathogenesis of Sporadic Parathyroid Adenomas and the Impact of Gender-Specific Epigenetic Regulation.
Yavropoulou MP; Poulios C; Michalopoulos N; Gatzou A; Chrisafi S; Mantalovas S; Papavramidis T; Daskalaki E; Sofou E; Kotsa K; Kesisoglou I; Zebekakis P; Yovos JG
Cells; 2018 Dec; 8(1):. PubMed ID: 30598042
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
